SLC5A2 and bacterial urinary tract infection: A meta-analysis of RCTs showed that SGLT-2 inhibitors were associated with UTI risks compared to placebo48, but other meta-analyses and pharmacoepidemiological studies found no link between SGLT-2 inhibitors and UTI risks26–31.